logo
  

Pfizer, Arvinas Ink Deal To Develop And Commercialize PROTAC Protein Degrader ARV-471 - Quick Facts

Pfizer Inc. (PFE) and Arvinas, Inc. (ARVN) announced Thursday a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.

The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor (ER) positive / human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.

Under the terms of the agreement, Pfizer will pay Arvinas $650 million upfront. Separately, Pfizer will make a $350 million equity investment in Arvinas to acquire an equity ownership stake of about 7 percent.

The companies will equally share worldwide development costs, commercialization expenses, and profits. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones, in addition to sharing profits on ARV-471 worldwide.

ARV-471 is the first PROTAC for breast cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer. Arvinas and Pfizer are seeking to develop ARV-471 as the potential endocrine therapy of choice for patients and their physicians.

ARV-471 currently is being evaluated as a treatment for metastatic breast cancer in a Phase 1 dose escalation study, a Phase 1b combination study with Pfizer's IBRANCE (palbociclib), and a Phase 2 monotherapy dose expansion study (VERITAC).

Arvinas and Pfizer expect to initiate two additional trials of ARV-471 in 2021. In 2022, Arvinas and Pfizer expect to initiate Phase 3 studies across lines of therapy in metastatic breast cancer, including combinations with IBRANCE, followed by pivotal studies in the early breast cancer setting.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple has updated its Apple Maps with the release of iOS 15 to now provide new ways to explore major cities through a new 3D view. Maps users on the new iOS in London, Los Angeles, New York City, and the San Francisco Bay Area can experience a three-dimensional city view of these major cities. Deutsche Lufthansa AG has launched additional flights to the United States on short notice, aiming to tap the surging demand following the planned end of U.S. travel restrictions. The German flag carrier is also increasing domestic flights to its European hubs amid high demand. Starting in October, the company is increasing German domestic flights by 45 percent, compared with July. Gas utility Southern California Gas Co. or SoCalGas and its parent company Sempra Energy announced agreements to resolve substantially all material civil litigation related to the 2015 Aliso Canyon natural gas storage facility leak. SoCalGas, which operates the storage facility, will record an after-tax charge of approximately $1.1 billion this month.
Follow RTT